arrow
K

Katherine B. Peters

Duke University Medical Center
H指数:46
被引数:9,352

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial

EGFR靶向抗体-毒素偶联物在复发性胶质瘤中的应用:一项1期临床试验

2026-10-160
PRE
NOTQ-04 NEUROCOGNITIVE OUTCOMES IN PATIENTS WITH BRAIN METASTASES: A SYSTEMATIC REVIEW OF PAST FINDINGS AND FUTURE DIRECTIONS

NOTQ-04 脑转移患者神经认知结局:既往发现和未来方向的系统综述

2026-08-070
OA
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma

Vorasanib在IDH突变胶质瘤的基因工程小鼠模型中改善了对后续放化疗的反应

2026-08-050
PRE
Neurocognitive outcomes in patients with brain metastases: a systematic review

脑转移瘤患者的神经认知结局:一项系统综述

2025-11-240
PRE
Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma

对 newly diagnosed high grade glioma 患者进行正念干预可行性的临床试验

2025-11-050
PRE
INVESTIGATION OF THE COMBINATION OF D2C7-IT WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) WHEN ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 COMPARED TO D2C7-IT CED MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

探究通过促进增强递送(CED)途径瘤内给药D2C7-IT与FC工程化抗人CD40单克隆抗体(2141-V11)联合应用,并随后进行2141-V11颈部淋巴周围注射(CPLIS)与D2C7-IT CED单药治疗相比,在复发性胶质母细胞瘤(RGBM)患者中的效果。

2025-11-010
OAAI
Aquaporin-4 loss in astrocytes drives glioblastoma-associated cerebral edema and alters the tumor immune microenvironment

水通道蛋白-4在星形胶质细胞中的丢失驱动胶质母细胞瘤相关的脑水肿并改变肿瘤免疫微环境

2025-11-010
OAAI
Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

与接受vorasidenib或安慰剂治疗的Grade 2,异柠檬酸脱氢酶1/2突变(mIDH1/2)胶质瘤患者中,体素(3D)评估相较于传统双向(2D)评估在INDIGO III期试验中的比较

2025-11-010
OAAI
A phase 2 double-blind, randomized, prospective, placebo-controlled study of NanO2TM combined with radiation and temozolomide in patients with newly diagnosed glioblastoma: RESTORE

一项关于NanO2TM联合放射治疗和替莫唑胺治疗新诊断胶质母细胞瘤的II期双盲、随机、前瞻性、安慰剂对照研究:RESTORE

2025-11-010
OAAI
Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

体积肿瘤生长率(TGR)建模预测了在INDIGO三期试验中,接受vorasidenib或安慰剂治疗的Grade 2、异柠檬酸脱氢酶1/2突变(mIDH1/2)胶质瘤患者的临床结局。

2025-11-010
OAAI
An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients

对Tumor Monorail Device (TMD)进行重复采样的评估,作为一项评估通过对流增强递送(CED)和颈周淋巴间隙注射(CPLIs)分别经瘤内给予D2C7-IT以及Fc工程化抗CD40单克隆抗体(2141-V11)的联合方案在复发性胶质母细胞瘤(rGBM)患者中疗效试验的一部分。

2025-11-010
OAAI